Spinal Muscular Atrophy: Updates in Clinical Trial Data and What Managed Care Professionals Need to Know, featuring a Patient Perspective
Biogen Inc. and Genentech, a member of the Roche Group.
Faculty Presenters
Alan Pannier, PharmD, MBA
Head of Clinical Services
SmithRx
Salt Lake City, Utah
Crystal Proud, MD
Neuromuscular Neurologist
Children’s Hospital of the King’s Daughters
Children’s Specialty Group
Norfolk, Virginia
Program Description
Approximately 9000 people in the United States are diagnosed with spinal muscular atrophy (SMA), and 1 in 50 people are carriers of the disease. Due to a high mortality rate associated with early-onset disease and different SMA type classifications, early intervention with genetic and newborn screening approaches is essential to predict severity and individualize patient treatment to control progression rates. Management of SMA has consisted primarily of supportive care to slow or prevent respiratory failure, nutritional compromise, and joint contractures. Patients with SMA who require supportive care for breathing difficulties, difficulty feeding and swallowing, and specialized occupational therapy incur exorbitant financial burden. Recently approved disease-modifying therapies have the potential to change the treatment landscape of SMA. As new data on the safety and efficacy of emerging treatments for SMA emerge, it is imperative that managed care professionals make informed decisions for optimal care of patients with this disease.
Target audience: Managed care, payer, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professionals who are interested in the management of spinal muscular atrophy.
Type of activity: Application
Release date: October 27, 2020
Expiration date: April 27, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
- Characterize the pathogenesis of spinal muscular atrophy (SMA) including its clinical presentation, classifications, diagnosis, and the need for early intervention
- Examine current and emerging treatment options for SMA including updated clinical trial data
- Explore the current guidelines for SMA and managed care implications for incorporating SMA therapies into treatment
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-323-H01-P. The activity is available for CE credit through April 27, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Crystal Proud, MD, has the following financial relationships with commercial interests to disclose:
Consultant: Biogen, AveXis
Speakers Bureau: Biogen, AveXis
Alan Pannier, PharmD, MBA, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Ann Marciano; Shawna Wilker; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Activity Disclaimer
Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this live CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
